Identification and Functional Characterization of Genes Encoding Phenylacetaldehyde Reductases That Catalyze the Last Step in the Biosynthesis of Hydroxytyrosol in Olive

The Role of Elderberry Hydrolate as a Therapeutic Agent in Palliative Care

Elderberry hydrolate, derived from the berries of Sambucus nigra, has gained attention for its therapeutic properties, particularly in skincare. This review explores its potential applications in palliative care, where patients often experience compromised skin health due to illness or treatment. The bioactive compounds in elderberry hydrolate, including phenylacetaldehyde, 2-acetyl-pyrrole, n-hexanal, furfural, and (E)-beta-damascenone, contribute to its anti-inflammatory, antioxidant, antimicrobial, and skin-healing effects. These properties make it a promising option for addressing common dermatological issues in palliative care, such as irritation, dryness, pruritus, and inflammation. For example, phenylacetaldehyde's antimicrobial and anti-inflammatory actions help soothe irritated skin, while 2-acetyl-pyrrole's antioxidant effects protect sensitive skin from oxidative stress. Additionally, n-hexanal's antimicrobial properties reduce infection risks and furfural aids in skin regeneration. (E)-beta-damascenone's antioxidant effects help maintain skin health and prevent further damage. Despite these promising effects, barriers to the widespread implementation of elderberry hydrolate in palliative care exist, including cost, accessibility, patient sensitivities, and regulatory challenges. Future research focusing on standardized chemical profiling, clinical trials, and addressing these practical concerns will be crucial for integrating elderberry hydrolate into palliative care regimens. This review highlights its potential as a natural, supportive therapy for enhancing patient comfort and quality of life in palliative care settings.

Genome assembly and multi-omics analyses of Isodon lophanthodies provide insights into the distribution of medicinal metabolites induced by exogenous methyl jasmonate

BACKGROUND

Isodon lophanthodies is a perennial herb and the whole plant has medicinal value distributed in southern China and southeast Asia. The absence of a reference genome has hindered evolution and genomic breeding research of this species.

RESULTS

In this study, we present a high-quality, chromosome-level genome assembly of I. lophanthodies with integrating PacBio and Hi-C sequencing data. We assembled a genome of 412.78 Mb with a scaffold N50 of ~ 33.43 Mb, organized into 12 pseudochromosomes. This assembly includes 36,324 genes and 209.51 Mb of repetitive sequences. Phylogenetic analysis revealed that I. lophanthodies and its sister species Isodon rubescens diverged approximately 9.99 million years ago (MYA), and shared a recent whole-genome duplication (WGD) event. Combined with the gene expression profile and metabolite fluctuation in response to methyl jasmonate, two key enzymes involved in salicin synthesis pathway were further identified.

CONCLUSIONS

This genome assembly provides an essential reference for future research on I. lophanthodies, and enhances our understanding of salicin synthesis and medicinal metabolite profiles in response to exogenous methyl jasmonate.

An engineered dual-functional L-DOPA decarboxylase enables a minimized hydroxytyrosol cascade

Hydroxytyrosol has been proven beneficial to human health. However, the process involving the conversion of L-DOPA to 3,4-dihydroxyphenylacetaldehyde (3,4-DHPAA) in hydroxytyrosol biosynthesis typically required the simultaneous use of decarboxylase and oxidative deaminase. In addition, phenylacetaldehyde reductase from Solanum lycopersicum (SlPAR) in hydroxytyrosol biosynthesis exhibits poor thermal stability. In this study, we unexpectedly discovered that L-DOPA decarboxylase from Pseudomonas putida (PpDODC) exhibits weak dual-functional activity for both decarboxylation and oxidative deamination of L-DOPA. Through a dual-function reshaping strategy, the best dual-functional mutant PpDODC/Y79F/Y324F achieved an enzyme activity of 0.95 U/mg and exhibited a 256.8-fold increase in activity compared to the wild-type. Through rational design of SlPAR, the optimal mutant SlPAR/G52D/V188I/N234W/Q286P (SlPAR-M4) maintained stability after 12 h' treatment at 40 °C. Based on these mutants, we established a simplified cascade to synthesize hydroxytyrosol from L-DOPA, achieving a hydroxytyrosol yield of 31.4 mM from 32 mM L-DOPA in a 5-hour reaction. This process achieved the highest molar conversion rate (98.2 %) currently reported for the synthesis of hydroxytyrosol from L-DOPA. This study provides a novel solution for hydroxytyrosol synthesis from a new perspective, and the mutants hold promise for widespread application in biotransformation studies of hydroxytyrosol and other structurally-similar compounds.

Biosynthesis and Biotechnological Synthesis of Hydroxytyrosol

Hydroxytyrosol (HT), a plant-derived phenolic compound, is recognized for its potent antioxidant capabilities alongside a spectrum of pharmacological benefits, including anti-inflammatory, anti-cancer, anti-bacterial, and anti-viral properties. These attributes have propelled HT into the spotlight as a premier nutraceutical and food additive, heralding a new era in health and wellness applications. Traditional methods for HT production, encompassing physico-chemical techniques and plant extraction, are increasingly being supplanted by biotechnological approaches. These modern methodologies offer several advantages, notably environmental sustainability, safety, and cost-effectiveness, which align with current demands for green and efficient production processes. This review delves into the biosynthetic pathways of HT, highlighting the enzymatic steps involved and the pivotal role of genetic and metabolic engineering in enhancing HT yield. It also surveys the latest progress in the biotechnological synthesis of HT, examining innovative strategies that leverage both genetically modified and non-modified organisms. Furthermore, this review explores the burgeoning potential of HT as a nutraceutical, underscoring its diverse applications and the implications for human health. Through a detailed examination of both the biosynthesis and biotechnological advances in HT production, this review contributes valuable insights to the field, charting a course towards the sustainable and scalable production of this multifaceted compound.

Countering Triple Negative Breast Cancer via Impeding Wnt/β-Catenin Signaling, a Phytotherapeutic Approach

Triple negative breast cancer (TNBC) is characterized as a heterogeneous disease with severe malignancy and high mortality. Aberrant Wnt/β-catenin signaling is responsible for self-renewal and mammosphere generation, metastasis and resistance to apoptosis and chemotherapy in TNBC. Nonetheless, in the absence of a targeted therapy, chemotherapy is regarded as the exclusive treatment strategy for the treatment of TNBC. This review aims to provide an unprecedented overview of the plants and herbal derivatives which repress the progression of TNBC through prohibiting the Wnt/β-catenin pathway. Herbal medicine extracts and bioactive compounds (alkaloids, retinoids. flavonoids, terpenes, carotenoids and lignans) alone, in combination with each other and/or with chemotherapy agents could interrupt the various steps of Wnt/β-catenin signaling, i.e., WNT, FZD, LRP, GSK3β, Dsh, APC, β-catenin and TCF/LEF. These phytotherapy agents diminish proliferation, metastasis, breast cancer stem cell self-renewal and induce apoptosis in cell and animal models of TNBC through the down-expression of the downstream target genes of Wnt signaling. Some of the herbal derivatives simultaneously impede Wnt/β-catenin signaling and other overactive pathways in triple negative breast cancer, including: mTORC1; ER stress and SATB1 signaling. The herbal remedies and their bioactive ingredients perform essential roles in the treatment of the very fatal TNBC via repression of Wnt/β-catenin signaling.